KOL Conversation: A New Treatment Option

In this KOL Conversation, Renee Pozza, NP, and Allysa Saggese, NP, explore the impact of newly FDA-approved therapies for Primary Biliary Cholangitis (PBC). They highlight the exciting potential of these treatments to improve symptom management, particularly pruritus, while offering enhanced safety profiles and greater flexibility in patient care.

This insightful exchange reflects the evolving landscape of liver disease management and offers valuable perspectives for healthcare providers.